Biotech & Pharma

Post-Hoc Live: What will the US government do about China biotech?

22 sec read58 views0 listens

The National Security Commission on Emerging Biotechnology warns the US is at risk of falling behind China in biotech innovation and will discuss policy recommendations to maintain leadership; the urgency stems from the commission's impending dissolution by year-end, highlighting critical timing for content creators covering biotech and regulatory affairs.

Read the full article at Endpoints News

Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

You Might Like

Legal & PolicyJun 2233 sec read

Fired a Medical Marijuana User After a Drug Test? A Pennsylvania Court Says Not So Fast.

A Pennsylvania federal court rejected federal preemption as a defense to terminating a medical marijuana cardholder, holding that Pennsylvania's state protections survive despite federal prohibition and that zero-tolerance policies inadequately addre...

Ali Nemati

Biotech & PharmaJun 532 sec read

STAT+: Pharmalittle: We're reading about Roche accusing U.S. of 'blackmail,' a ruling on skinny labels, and more

The FDA is reviewing its expedited drug review program following feedback from patient groups and companies, with many urging a pause for more public input. In parallel, the FDA has initiated a safety study of the mifepristone abortion pill, which co...

Ali Nemati

Legal & PolicyJun 432 sec read

Court rules against cell service providers over right to jury trial in FCC proceedings

The Supreme Court has ruled against AT&T and Verizon, upholding the FCC's authority to impose sanctions for telecommunications law violations without requiring an initial jury trial. The Court determined that the Seventh Amendment's right to a ju...

Ali Nemati